Publications by authors named "M A Girondo"
Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial.
Trials
January 2024
Background: Autoimmune hepatitis (AIH) is a rare, chronic inflammatory disease of the liver. The treatment goal is reaching complete biochemical response (CR), defined as the normalisation of aspartate and alanine aminotransferases and immunoglobulin gamma. Ongoing AIH activity can lead to fibrosis and (decompensated) cirrhosis.
View Article and Find Full Text PDFArticle Synopsis
- T-cell activity is suppressed in ER+ breast cancer when PD-1 binds PD-L1 or PD-L2, raising the need for better ways to predict who will respond to treatments like PD-1 inhibitors.
- This study focused on measuring PD-L2 protein levels in patients with therapy-naive ER+ breast cancer and correlated these levels with progression-free survival (PFS) across two cohorts.
- Results showed that high PD-L2 expression in cancer cells was linked to shorter PFS, suggesting that high PD-L2 levels can be an important marker to identify patients at greater risk of early recurrence.
Background: The United States is in an opioid epidemic. Passive decision support in the electronic health record (EHR) through opioid prescription presets may aid in curbing opioid dependence.
Objective: The objective of this study is to determine whether modification of opioid prescribing presets in the EHR could change prescribing patterns for an entire hospital system.
Background: The United States is in the midst of an opioid epidemic. Long-term use of opioid medications is associated with an increased risk of dependence. The US Centers for Disease Control and Prevention makes specific recommendations regarding opioid prescribing, including that prescription quantities should not exceed the intended duration of treatment.
View Article and Find Full Text PDFPurpose: Parathyroid hormone-related protein (PTHrP) is required for normal mammary gland development and biology. A gene polymorphism is associated with breast cancer risk, and PTHrP promotes growth of osteolytic breast cancer bone metastases. Accordingly, current dogma holds that PTHrP is upregulated in malignant primary breast tumors, but solid evidence for this assumption is missing.
View Article and Find Full Text PDF